PBLS — Parabilis Medicines, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1657677 ·
Last close
$28.25
Market Cap
$3.49B
52W High
$42.49
52W Low
$22.66
ADV30
1,017,056
Next earnings
2026-11-12
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 148,000 — -50,886,000 -52,463,000 1,175,262,000 1,087,060,000 127,528,000
Mar 2026 0 — -47,453,000 -45,316,000 384,173,000 329,039,000 139,953,000
Dec 2025 0 — -40,473,000 -39,278,000 80,820,000 27,711,000 97,344,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-118,066,000
Investing CF
$-3,232,000
Financing CF
$1,213,757,000
CapEx
$-1,075,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.26
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-639,283,000
Inventory
—
Receivables
—
ST Investments
$33,637,000
EBIT TTM
$-169,618,000
Pretax Income TTM
$-170,915,000
Interest Exp TTM
$1,297,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,262,000
EBITDA
$-190,072,000
Free Cash Flow
—
Enterprise Value
$2,731,282,944
Total Cash
$871,622,976
Total Debt
$41,826,000
Shares Out
123,676,615
Trailing EPS
$-9.76
Book Value
$-168.09
ROE
—
ROA
—
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -152,079,000 -145,889,000 80,820,000 97,344,000 -16,524,000 -123,713,000
Dec 2024 0 -126,125,000 -117,914,000 149,253,000 92,814,000 56,439,000 -103,613,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,175,262,000
Forward EPS
$-2.35

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $35.00 · spot: $28.47 · call volume: 14 · put volume: 32
Expected Move to 2027-02-19: ±$9.00 (31.61%) — implied range $19.47 – $37.47 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IRON Disc Medicine, Inc. $3.49B $76.57 —
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —
VKTX Viking Therapeutics, Inc. $3.43B $26.88 —

News headlines (Yahoo Finance, 1h cache)

Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
2026-11-17 13:55 · Yahoo
Parabilis Medicines: Q3 Earnings Snapshot
2026-11-12 12:38 · Yahoo
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 12:00 · Yahoo
Parabilis Medicines to Participate in Upcoming November Investor Conferences
2026-11-03 12:00 · Yahoo
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
2026-10-24 21:02 · Yahoo
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
2026-10-24 12:45 · Yahoo
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
2026-10-20 20:06 · Yahoo
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
2026-10-20 19:12 · Yahoo
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
2026-10-20 18:17 · Yahoo
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
2026-10-19 17:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.